Risperdal Lawsuits Surge in Philadelphia Mass Tort
The inventory of Risperdal lawsuits tied to allegations against the manufacturer that patients were never warned about the side effects of the medication, including gynecomastia, have increased dramatically.
The pharma related mass tort programs currently being managed in Philadelphia and tied to most Risperdal lawsuits around the country has reached a record high for the second year in a row.
The latest statistics surrounding the number of Risperdal lawsuits managed in this program indicate that from the beginning of 2017, the number of total mass tort programs within Philadelphia increased by more than 77 percent and pharmaceutical cases represented a significant portion of that.
At the beginning of 2017, there were more than 5,600 pharmaceutical cases including Risperdal lawsuits, reaching a record for the court. The latest statistics indicated that the pharmaceutical cases currently consolidated in Philadelphia hit an 85.5 percent increase.
The primary driver of this growth in these legal claims include the Risperdal lawsuits which make up more than half of the total mass tort inventory in Philadelphia.
The number of Risperdal lawsuits in the courts since early 2017 increased from 1,945 to 6,200 by the end of the year, representing more than a 219 percent jump over that 12-month period.
Although it is not expected that another wave of lawsuits will be filed soon, more patients do continue to come forward and purport that the manufacturer knew about the dangerous and embarrassing side effects and risks, including the development of gynecomastia.
Another driver for the rise in Risperdal lawsuits had to do with the fact that there was a recent state superior court ruling, allowing plaintiffs to sue for punitive damages, which may put additional pressure on the defendants.
Another new high recorded for Risperdal lawsuits had to do with the percentage of plaintiffs from out of state filing cases in Philadelphia.
The number of out of state plaintiffs filing Risperdal lawsuits in 2017 increased to 90 percent and this is the highest number since the court first began capturing the statistic in 2005.
Risperdal, when released to the market, came with some limited information about the kinds of side effects that users might experience.
Commonly given to patients suffering from schizophrenia, the drug has also been tied to off-label uses.
When used with young men or boys, either for on-label or off-label reasons, these patients could develop gynecomastia.
When this occurs, surgical removal might be the only way to treat the development of breast tissue.
Those patients who have been allegedly harmed by Risperdal and other pharmaceutical creations may be eligible to file lawsuits against the manufacturers that they have suffered devastating side effects or the loss of a loved one about which they were never warned. Many families have been touched by the issues surrounding Risperdal.
Risperdal lawsuits have become especially prominent in recent years due to the number of young men and boys who developed gynecomastia or breast tissue and many of these plaintiffs say that they were never told about the possibility of suffering from this kind of side effect.
The experienced attorneys at McDonald Worley offer a free case evaluation. Call today!
Disclaimer: McDonald Worley is not representing the plaintiff in this lawsuit.